Abiraterone-Acetate shortage — IT supply status & alternatives

Abiraterone-Acetate

ATC L02BX03

Anticipated · Australia

ABIRATERONE-TEVA abiraterone acetate

Anticipated · 🇦🇺 Australia & also short in🇮🇹 IT🇨🇦 CA

Anticipated shortage

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Oct 2026

Sponsor est. via TGA

Product attributes reference data we hold

Active ingredient (INN)	Abiraterone-Acetate
Brand names	ABIRATERONE-TEVA abiraterone acetate

ATC level 4	L02BX

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇦🇺 31 Aug 2026

low reported

🇮🇹 15 July 2026

critical reported

🇨🇦 8 June 2026

medium reported

🇮🇹 20 Mar 2025

critical reported

🇮🇹 30 June 2024

Shortage resolved

🇮🇹 26 Jan 2023

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.